Home › Calculator › ESALF Dividend Calculator 2026
ESALF Dividend DRIP Calculator 2026
3.63% YieldHealthcareEisai Co., Ltd. · OTC
Price: $28.71 · Annual div: $1.04/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When ESALF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your ESALF snowball 📈
$10,000 in ESALF → $162.7K in 10 years · $36.24/month
About Eisai Co., Ltd. (ESALF) — Dividend Analysis 2026
Eisai Co., Ltd., a pharmaceutical company headquartered in Tokyo, Japan, develops and markets a wide array of medicinal products. Its offerings for neurological conditions include Aricept, prescribed for Alzheimer's disease and dementia with Lewy bodies; Methycobal, used to treat peripheral neuropathy; Fycompa, an antiepileptic drug that serves as an adjunctive therapy for specific partial-onset and primary generalized tonic-clonic seizures; Lyrica, for various pain management needs; and Dayvigo, an anti-insomnia medication for adults. In the oncology field, Eisai provides Lenvima, a molecularly targeted anticancer agent for thyroid cancer, renal cell carcinoma (when used in combination with everolimus), and hepatocellular carcinoma. Another key cancer treatment is Halaven, a microtubule dynamics inhibitor for breast cancer and liposarcoma. The company's portfolio also features Pariet, a proton-pump inhibitor effective in treating gastric and duodenal ulcers, reflux esophagitis, and for the eradication of Helicobacter pylori infections. Additionally, Eisai markets Humira, a fully human anti-TNF-alpha monoclonal antibody employed in managing autoimmune diseases such as rheumatoid arthritis. Beyond prescription medicines, Eisai provides consumer health products like Chocola BB Plus, a vitamin B2 preparation addressing rough skin and stomatitis, alongside various third-class over-the-counter (OTC) drugs, designated quasi-drugs, and functional foods. The company was established in 1941, initially operating as Nihon Eisai Co., Ltd., before adopting its current name, Eisai Co., Ltd., in 1955.
Compare ESALF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full ESALF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ESALF position with:
🌍 ESALF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ESALF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 3.63% | 0.83% | $363 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 3.09% | 0.29% | $309 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2.90% | 0.10% | $290 / yr |
| 🇬🇧 UK ISA | 0% | 3.63% | 0.83% | $363 / yr |
| 🇬🇧 UK Taxable | 8.75% | 3.31% | 0.51% | $331 / yr |
| 🇨🇦 TFSA | 0% | 3.63% | 0.83% | $363 / yr |
| 🇨🇦 CA Taxable | 25% | 2.72% | -0.08% | $272 / yr |
| 🇦🇺 Super (pension) | 15% | 3.09% | 0.29% | $309 / yr |
| 🇦🇺 AU Taxable | 30% | 2.54% | -0.26% | $254 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2.67% | -0.13% | $267 / yr |
| 🇫🇷 FR Taxable | 30% | 2.54% | -0.26% | $254 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ESALF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $1.04/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ESALF Dividend Payment Schedule
ESALF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 ESALF vs Healthcare Benchmarks
How ESALF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ESALF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ESALF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ESALF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Eisai Co., Ltd. (ESALF) is currently trading at $28.71, 72% below its 52-week high. The current dividend yield is 3.63% based on an annual payout of $1.04 per share.
ESALF (Eisai Co., Ltd.) — 3.63% Dividend Yield Analysis
Eisai Co., Ltd. (ESALF) is a healthcare stock currently trading at $28.71 with a dividend yield of 3.63%. The company pays an annual dividend of $1.04 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, ESALF has grown its dividend at a compound annual rate of 0.7%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest ESALF News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.